Kidney Disease Clinical Trials in Los Angeles

Showing 81-100 of 177 trials

High Dose IL 2 and Entinostat in RCC

NCT03501381

This is a multicenter, randomized, open label study of high dose interleukin 2 vs high dose interleukin 2 plus entinostat in clear cell RCC patients who are candidate for high dose interleukin 2. Patients will be randomized to ARM 1 (high dose interleukin 2 plus entinostat) or ARM 2 (high dose interleukin 2). Subjects will receive up to 3 courses of high dose interleukin 600,000 units/kg administered IV every 8 hrs on Days 1-5 and Days 15-19 (maximum 28 doses) +/- entinostat 5 mg orally given every 2 weeks starting on Day-14, continuously. Tumor response assessment will be performed between HD IL-2 courses.

Renal Cell Carcinoma

Roberto Pili46 participantsStarted May 2018

Los Angeles, California, United States • Chicago, Illinois, United States • Indianapolis, Indiana, United States +2 more locations

COMPLETEDNA< 1 mile

Look AHEAD: Action for Health in Diabetes

NCT00017953

The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.

DiabetesMyocardial InfarctionStroke+3 more

Wake Forest University Health Sciences5,145 participantsStarted Jun 2001

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +15 more locations

High Dose IL 2 and Entinostat in RCC

Look AHEAD: Action for Health in Diabetes

Kidney Disease Trials in Other Cities

Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Androgen Reduction in Congenital Adrenal Hyperplasia

Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

Assess Safety and Performance of the Kronos Electrocautery Device for Electrocautery Procedures Following Coaxial Biopsy Procedures

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Other Conditions in Los Angeles